Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2935 Results for "
paracetamol-induced hepatic damage
" in MedChemExpress (MCE) Product Catalog:
Products (2935)
2935 Results for "paracetamol-induced hepatic damage" in MCE Product Catalog:
1851
1851 Publications Verification
Synonyms: Fer-1
Target:
Research Areas:
Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .
899
899 Cited Publications
Cat. No.: HY-17394
CAS No.: 15663-27-1
Synonyms: cis-Platinum; CDDP; cis-Diaminodichloroplatinum
Research Areas:
Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
245
245 Cited Publications
Cat. No.: HY-17371
CAS No.: 61825-94-3
Target:
Research Areas:
Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .
226
226 Cited Publications
Cat. No.: HY-17565A
CAS No.: 67763-87-5
Target:
Research Areas:
Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic .
226
Category:
Antibiotics Resistance Selection Mammalian Cell Culture Microorganism Disease Research Anticancer Disease Research Fields Other Antibiotics Cancer
Target:
191
191 Cited Publications
Cat. No.: HY-D0814
CAS No.: 28718-90-3
Synonyms: 4',6-Diamidino-2-phenylindole dihydrochloride
191
191 Cited Publications
Cat. No.: HY-D2868
CAS No.: 47165-04-8
Synonyms: 4',6-Diamidino-2-phenylindole
185
185 Cited Publications
Cat. No.: HY-D1738
CAS No.: 28718-91-4
Synonyms: 4',6-Diamidino-2-phenylindole dilactate
183
183
Research Areas:
Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research .
172
172 Cited Publications
Cat. No.: HY-D0815
CAS No.: 25535-16-4
168
168 Cited Publications
Synonyms: MitoQ mesylate; MitoQ10 mesylate
Target:
Research Areas:
Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage .
154
154 Cited Publications
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways .
122
122 Cited Publications
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis .
114
114 Cited Publications
Cat. No.: HY-19696B
CAS No.: 117609-50-4
Synonyms: Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate
102
102 Cited Publications
Cat. No.: HY-128868
CAS No.: 60842-46-8
102
102 Cited Publications
Cat. No.: HY-128868A
CAS No.: 60842-46-8
92
91
91 Cited Publications
Synonyms: MK-4827 tosylate
Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
91
Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
